Sugi Predict

Sugi Predict / Compounds / SCHEMBL7513399

SCHEMBL7513399

SCHEMBL7513399

COc1cc(B2OC(C)(C)C(C)(C)O2)ccc1C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ CSF1R P07333 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ SNCA P37840 1/20 0.41
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ LPL P06858 5/20 0.39
▸ LIPG Q9Y5X9 5/20 0.39
▸ CA12 O43570 1/20 0.37
▸ CA3 P07451 1/20 0.37
▸ CA4 P22748 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL552983 0.88 CSF1R (0.45) ALDH1A1CSF1RKDM4ETSHRTDP1
SCHEMBL31556836 0.85 CSF1R (0.37) ALDH1A1CSF1RL3MBTL1SNCACA1
SCHEMBL20504766 0.84 LPL (0.41) ALDH1A1CSF1RKDM4EL3MBTL1CA1
SCHEMBL23783217 0.83 LPL (0.38) ALDH1A1CSF1RSNCACA1CA2
SCHEMBL21497020 0.83 LPL (0.38) ALDH1A1CSF1RSNCACA1CA2
SCHEMBL4477463 0.82 LMNA (0.49) ALDH1A1CSF1RSNCACA1CA2
SCHEMBL27079999 0.81 ALDH1A1 (0.43) ALDH1A1CSF1RKDM4ETSHRTDP1
SCHEMBL1877988 0.80 CSF1R (0.48) CSF1RSNCACA1CA2CA9
SCHEMBL25203373 0.80 CSF1R (0.48) CSF1RSNCACA1CA2CA9
SCHEMBL30836767 0.80 LPL (0.42) ALDH1A1CSF1RTSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042779-A1 SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORPORATION (CA) 2026-02-12 — — US disclosed
EP-4573100-A1 SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF Arbutus Biopharma Corporation (CA) 2025-06-25 — — EP disclosed
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE C4 THERAPEUTICS, INC. 2024-08-29 — — US disclosed
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-25 — — US disclosed
WO-2024134466-A1 SUBSTITUTED ARYLAMINE COMPOUNDS, SUBSTITUTED HETEROARYLAMINE COMPOUNDS, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-06-27 — — WO disclosed
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-25 — — US disclosed
WO-2024069448-A1 SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-04-04 — — WO disclosed
EP-4333899-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2024-03-13 — — EP disclosed
WO-2024038356-A1 SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF ARBUTUS BIOPHARMA CORPORATION (CA) 2024-02-22 — — WO disclosed
CN-117580592-A Compounds for targeting bruton's tyrosine kinase degradation 渤健马萨诸塞州股份有限公司 2024-02-20 — — CN disclosed
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 — — US disclosed
EP-2925319-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES University Of Rochester (US) 2015-10-07 — — EP disclosed
WO-2014170248-A1 ARYLPYRROLOPYRIDINE DERIVED COMPOUNDS AS LRRK2 INHIBITORS H. LUNDBECK A/S (DK) 2014-10-23 — — WO disclosed
US-20140315901-A1 Arylpyrrolopyridine derived compounds as LRRK2 inhibitors H. LUNDBECK A/S (DK) 2014-10-23 — — US disclosed
US-8846909-B2 Bicyclic heteroaryl kinase inhibitors and methods of use UNIVERSITY OF ROCHESTER (US) 2014-09-30 — — US disclosed
WO-2014085795-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIVERSITY OF ROCHESTER (US) 2014-06-05 — — WO disclosed
US-20130203755-A1 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2013-08-08 — — US disclosed
EP-2576549-A2 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE University of Rochester (US) 2013-04-10 — — EP disclosed
WO-2011149950-A2 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2011-12-01 — — WO disclosed
WO-2011115183-A1 NOVEL MONOCYCLIC PYRIMIDINE DERIVATIVE 大日本住友製薬株式会社 (JP) 2011-09-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES MLKL, MARCKS, MAP3K4 ALDH1A1 4296/4885CSF1R 1258/4885KDM4E 2231/4885
US-20260042779-A1 SYNTHESIS OF SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS AND SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND ANALOGUES THEREOF HAVCR2, NNMT, DOHH ALDH1A1 584/4885CSF1R 4792/4885KDM4E 2605/4885
US-20240287076-A1 COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, SYK, LYN ALDH1A1 3476/4885CSF1R 2652/4885KDM4E 772/4885
US-20240246964-A1 SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME HAVCR2, HDGF, HCCS ALDH1A1 382/4885CSF1R 2930/4885KDM4E 840/4885
US-20130203755-A1 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE MAP2K2, MAP2K7, CHKB ALDH1A1 2788/4885CSF1R 3502/4885KDM4E 1591/4885
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP MGMT, MCL1, FANCF ALDH1A1 446/4885CSF1R 4249/4885KDM4E 1910/4885
US-20140315901-A1 Arylpyrrolopyridine derived compounds as LRRK2 inhibitors LRRK2, PARK7, SNCA ALDH1A1 1119/4885CSF1R 923/4885KDM4E 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.